Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation
| dc.contributor.author | Melendez-Torres, G. J. | |
| dc.contributor.author | Auguste, Peter | |
| dc.contributor.author | Armoiry, Xavier | |
| dc.contributor.author | Maheswaran, Hendramoorthy | |
| dc.contributor.author | Court, Rachel | |
| dc.contributor.author | Madan, Jason | |
| dc.contributor.author | Kan, Alan | |
| dc.contributor.author | Lin, Stephanie | |
| dc.contributor.author | Counsell, Carl | |
| dc.contributor.author | Patterson, Jacoby | |
| dc.contributor.author | Rodrigues, Jeremy | |
| dc.contributor.author | Ciccarelli, Olga | |
| dc.contributor.author | Fraser, Hannah | |
| dc.contributor.author | Clarke, Aileen | |
| dc.contributor.institution | University of Aberdeen.Chronic Disease Research Group | en |
| dc.contributor.institution | University of Aberdeen.Grampian Data Safe Haven (DaSH) | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.date.accessioned | 2017-09-28T09:00:19Z | |
| dc.date.available | 2017-09-28T09:00:19Z | |
| dc.date.issued | 2017-09-01 | |
| dc.description | The authors gratefully acknowledge the assistance of Ms Karoline Munro and Dr Martin Connock. The authors also acknowledge the work and assistance of Charles Dobson and the RSS Steering Group. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 352 | |
| dc.format.extent | 2986280 | |
| dc.identifier | 108944767 | |
| dc.identifier | 6b8ae18f-7010-42d1-87c3-e125c6387795 | |
| dc.identifier | 85030177121 | |
| dc.identifier.citation | Melendez-Torres, G J, Auguste, P, Armoiry, X, Maheswaran, H, Court, R, Madan, J, Kan, A, Lin, S, Counsell, C, Patterson, J, Rodrigues, J, Ciccarelli, O, Fraser, H & Clarke, A 2017, 'Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation', Health Technology Assessment, vol. 21, no. 52, pp. 1-352. https://doi.org/10.3310/hta21520 | en |
| dc.identifier.doi | 10.3310/hta21520 | |
| dc.identifier.iss | 52 | en |
| dc.identifier.issn | 1366-5278 | |
| dc.identifier.other | ORCID: /0000-0001-6622-7839/work/164505733 | |
| dc.identifier.uri | http://hdl.handle.net/2164/9366 | |
| dc.identifier.vol | 21 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Health Technology Assessment | en |
| dc.subject | R Medicine (General) | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject.lcc | R1 | en |
| dc.title | Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation | en |
| dc.type | Journal article | en |
